Approaches in the Management of Hepatocellular
Carcinoma(HCC): What Managed Care Needs to Know
About Emerging Combination
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of HCC, including
how to translate the most recent data into clinical and
These are archives of live webinars held between March 18 to April
If you participated in any of the live webinars, you are not
claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
Each session has its own specific valid dates
This series is supported by educational
Eisai and Merck & Co.
This activity is intended for healthcare professionals practicing in managed
Instructions for CME/CNE: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
Hepatocellular carcinoma (HCC) is the most common
type of liver cancer, accounting for about 90% of cases of primary liver cancer
in the US. In 2019, it was expected that liver cancer accounted for
approximately 788,000 deaths globally, making it the second leading cause of
cancer-related deaths worldwide. Prognosis is especially poor for those with
unresectable HCC. Fortunately, new agents have recently been approved that
provide new options for clinicians in the first-line setting. Additionally,
targeted therapy and immunotherapy combinations have shown improved efficacy and
safety in recent clinical trials. In this webinar series, attendees will learn
about the latest data necessary to make appropriate formulary decisions and care
for patients with HCC around these targeted and immunotherapy combination
options, especially as more are approved and become available.